The Supreme Court of Canada today delivered an important and highly anticipated decision, AstraZeneca Canada Inc v Apotex Inc (2017 SCC 36), by rejecting the “promise doctrine” and clarifying the requirement for patent “utility” in Canada. The unanimous decision represents an important victory for innovators seeking protection in Canada, and is especially welcome in the highly litigated area of pharmaceutical patents.
AstraZeneca was successfully represented before the Supreme Court of Canada by Gunars A Gaikis, Yoon Kang and Lynn Ing of Smart & Biggar.
The so-called “promise doctrine” developed by the Federal Courts in recent years had become the yardstick against which utility is measured. This had become a highly contentious issue as it resulted in the invalidity of numerous pharmaceutical patents. The Supreme Court fully rejected the doctrine as “incongruent with both the words and the scheme of the Patent Act”.
In the case under appeal, the Court considered AstraZeneca’s patent covering the compound esomeprazole in Nexium, AstraZeneca’s successful proton pump inhibitor (PPI) drug that reduces gastric acid and treats maladies such as reflux esophagitis. The patent was found novel and unobvious at trial (2014 FC 638), but invalid for lack of utility.
Applying the promise doctrine, the trial judge had identified two promises: as a PPI, and “improved pharmacokinetic and metabolic properties which would give an improved therapeutic profile such as a lower degree of interindividual variation”. There was no dispute the first utility was soundly predicted, but the second was held to not be demonstrated or soundly predicted at the filing date. The Federal Court of Appeal upheld this decision (2015 FCA 158).
The Supreme Court’s total rejection of the promise doctrine is clear: “The Promise Doctrine is not the correct method of determining whether the utility requirement under s. 2 of the Patent Act is met”; “it is not good law” and is “unsound”.
The Court found the promise doctrine is excessively onerous in two ways: (1) it determines the standard of utility that is required of a patent by reference to the promises expressed in the patent; and (2) where there are multiple expressed promises of utility, it requires that all be fulfilled for a patent to be valid.
The Court set out the correct approach, as follows:
 …. ultimately, every invention pertains to a single subject-matter, and any single use of that subject-matter that is demonstrated or soundly predicted by the filing date is sufficient to make an invention useful for the purposes of s. 2.
 Utility will differ based on the subject-matter of the invention as identified by claims construction. Thus, the scope of potentially acceptable uses to meet the s. 2 requirement is limited – not any use will do. By requiring the usefulness of the proposed invention to be related to the nature of the subject-matter, a proposed invention cannot be saved by an entirely unrelated use. It is not sufficient for a patentee seeking a patent for a machine to assert it is useful as a paperweight.
 To determine whether a patent discloses an invention with sufficient utility under s. 2, courts should undertake the following analysis. First, courts must identify the subject-matter of the invention as claimed in the patent. Second, courts must ask whether that subject-matter is useful — is it capable of a practical purpose (i.e. an actual result)?
 The Act does not prescribe the degree or quantum of usefulness required, or that every potential use be realized — a scintilla of utility will do. A single use related to the nature of the subject-matter is sufficient, and the utility must be established by either demonstration or sound prediction as of the filing date…
Applying the correct approach, the Supreme Court found AstraZeneca’s patent was valid. At trial, the judge had found the claimed subject-matter – the optically pure salts of the enantiomer of omeprazole – to be useful for a purpose, as a proton pump inhibitor to reduce production of gastric acid. That use was sufficient utility to make the subject-matter useful within the meaning of s. 2.
The Supreme Court accordingly allowed AstraZeneca’s appeal.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
On February 7, 2024, the Federal Court dismissed Takeda’s action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to dexlansoprazole (Takeda’s DEXILANT).Read More
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More
Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatmentOn February 1, 2024, the Federal Court of Appeal (FCA) dismissed Pharmascience’s appeal. Per the FCA, whether a claimed dosing regimen is an unpatentable method of medical treatment cannot be based ex...Read More